Keith Speights

Keith Speights

TMFFishBiz

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles






Is GW Pharmaceuticals a Buy?

To buy or not to buy? That's the question for GW Pharmaceuticals. And here's the answer.







3 Stocks to Build Your Portfolio Around

Some stocks you merely buy. Others are at the core of your portfolio. These three belong in the latter category.





Is Amgen a Buy?

The biotech's present and future might not live up to its past.